48 results on '"Utsumi F"'
Search Results
2. ChemInform Abstract: The Reactions of Monoalkylthio- or Monoarylthio-Substituted Cyclopropenium Salt with Nitrogen Nucleophiles: Formation of Polyfunctionally Substituted Pyrroles or Pyrazoles.
- Author
-
YOSHIDA, H., primary, UTSUMI, F., additional, SUZUKI, H., additional, ITO, S., additional, SAKASHITA, S., additional, OGATA, T., additional, and MATSUMOTO, K., additional
- Published
- 2010
- Full Text
- View/download PDF
3. ChemInform Abstract: The Reactions of Monoalkylthio- or Monoarylthio-Substituted Cyclopropenium Salt with Nitrogen Nucleophiles: Formation of Polyfunctionally Substituted Pyrroles or Pyrazoles.
- Author
-
YOSHIDA, H., UTSUMI, F., SUZUKI, H., ITO, S., SAKASHITA, S., OGATA, T., and MATSUMOTO, K.
- Published
- 1992
- Full Text
- View/download PDF
4. ChemInform Abstract: Preparation of 3,3-Bis(phosphoryl)cyclopropenes.
- Author
-
YOSHIDA, H., AOYAMA, M., UTSUMI, F., OGATA, T., and MATSUMOTO, K.
- Published
- 1992
- Full Text
- View/download PDF
5. A case of ovarian serous cystadenofibroma with scattered lesions in pelvic cavity, like malignant disseminations.
- Author
-
Fujita K, Ogawa C, Sako T, Utsumi F, Inada KI, and Shibata K
- Subjects
- Adult, Fallopian Tubes, Female, Humans, Young Adult, Cystadenofibroma diagnosis, Cystadenofibroma surgery, Cystadenoma, Serous diagnosis, Cystadenoma, Serous surgery, Ovarian Neoplasms diagnosis, Ovarian Neoplasms surgery
- Abstract
Ovarian serous cystadenofibroma is a relatively rare subtype of serous cystadenoma classified as ovarian benign epithelial tumor. We report a rare case of ovarian serous cystadenofibroma with scattered lesions in pelvic cavity, like malignant disseminations. The patient was 22 years old, gravida 0, para 0. In the laparoscopic surgery, numerous hard yellowish-white solid masses of various sizes were present in the bilateral ovaries. Grossly similar masses were scattered in the fimbria of the fallopian tubes, peritoneum, and great omentum. Because the intraoperative rapid histological diagnosis was benign tumor, surgery was completed for only tumor excision. Postoperative histopathological diagnosis is serous cystadenofibroma. Similar pathological findings were noted in the scattered lesions in the peritoneum and great omentum. No malignant or borderline malignant finding was observed. Because of a benign disease, careful treatment taking fertility preservation into consideration is necessary, especially for young patients., (© 2021 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.)
- Published
- 2021
- Full Text
- View/download PDF
6. [Cooperative Surgery with Gastroenterological Surgeons in Gynecologic Malignant Tumors].
- Author
-
Arakawa S, Asano Y, Kato H, Shimura M, Koike D, Hayashi C, Ochi T, Kamio K, Kawai T, Yasuoka H, Higashiguchi T, Ito M, Utsumi F, Shibata K, and Horiguchi A
- Subjects
- Female, Humans, Neoplasm Recurrence, Local, Genital Neoplasms, Female surgery, Gynecology, Intestinal Diseases, Surgeons
- Abstract
Secondary debulking surgery(SDF)for gynecologic malignancies may improve prognosis. However, recurrent lesions may be invasions of the intestinal tract and observed peritoneal dissemination. SDF can be safely carried out by performing cooperative surgery with a gastroenterological surgeon and gynecologists. Precise cooperation is indispensable for the operation, especially when it comes to aspects such as the contact method and perioperative management at that time. In our hospital, if the gynecologist suspects other organs invasion during a preoperative examination, they contact the gastroenterological surgeon in an elective manner. If other organs invasion is not clear during a preoperative examination or bowel injury occurs during surgery, the gastroenterological surgeon would be contacted urgently. To ensure smooth cooperation, it is necessary to run regular joint conferences. By sharing in planned and combining the expertise of all the department of interest, it is possible to perform highly curative and safe surgery.
- Published
- 2021
7. Survival after Anticancer Treatment of Terminally Ill Patients with Ovarian Carcinoma.
- Author
-
Kajiyama H, Suzuki S, Shimbo A, Utsumi F, Yoshikawa N, and Kikkawa F
- Subjects
- Cohort Studies, Female, Humans, Proportional Hazards Models, Retrospective Studies, Ovarian Neoplasms drug therapy, Terminally Ill
- Abstract
Background: It remains unclear whether the end-of-life (EOL) treatment/environment impacts on survival after anticancer treatment in terminally ill women with ovarian carcinoma (OC). Objective: The aim of this investigation was to clarify how long those women actually survived after their last anticancer treatments and their hallmarks. Setting, Design, and Measurements: Between 2003 and 2011, 79 terminally ill women with OC were retrospectively analyzed as a single institutional study. Postcancer treatment survival (PCS), defined as the duration between the last date of the abovementioned "cancer treatment" and that of death from any cause, was analyzed on stratification by type of supportive care or where patients spend their EOL. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier and Cox regression analyses were employed to compare PCS between the two groups. Results: The median PCS of patients was 10.8 weeks. In the multivariable analysis, the performance status and EOL place retained their significance as independent prognostic factors of poorer PCS (performance status [2-3/0-1]: hazard ratio [HR] = 3.279 [95% confidence interval; CI 1.967-5.586; p < 0.0001], EOL place [hospital/home hospice]: HR = 0.574 [95% CI 0.355-0.913; p = 0.0188]). In the IPTW-adjusted cohort, the median PCS rates were 15.0 and 9.7 weeks in patients of home/hospice and hospital groups, respectively ( p = 0.04). Also in the IPTW cohort, the EOL place retained its significance (IPTW-adjusted: HR [95% CI]: 1.548 [1.009-2.374], p = 0.045, multivariable adjusted with IPTW: HR [95% CI]: 1.670 [1.077-2.588], p = 0.022). Conclusion: Our current data may be hypothesis generating; it is possible that the EOL environment is a crucial prognostic factor for survival after anticancer treatment.
- Published
- 2020
- Full Text
- View/download PDF
8. The Therapeutic Effects of Goreisan, a Traditional Japanese Herbal Medicine, on Lower-Limb Lymphedema after Lymphadenectomy in Gynecologic Malignancies: A Case Series Study.
- Author
-
Yoshikawa N, Kajiyama H, Otsuka N, Tamauchi S, Ikeda Y, Nishino K, Niimi K, Suzuki S, Utsumi F, Shibata K, and Kikkawa F
- Abstract
Background: Lower-limb lymphedema (LLL) is a chronic and progressive complication of gynecologic cancer treatment, including pelvic lymphadenectomy. This study aims to investigate the therapeutic effect of goreisan, a traditional Japanese medicine, which has been used for hydrostatic modulation on patients with LLL., Methods: Patients diagnosed with LLL in our hospital in 2018 were included and principally treated with complex decongestive therapy (CDT), including elastic clothing and lymph drainage. The patients who received a combination therapy of CDT and goreisan (CDT-G group) were prescribed goreisan extract granules, with a dose of 7.5 g per os daily in three doses. Patients who were not prescribed goreisan received CDT alone (CDT group). The severity of lymphedema was evaluated by the estimated limb volume calculated by limb circumferences and the ratio of extracellular water (ECW) to total body water (TBW)., Results: Nineteen women with LLL after pelvic lymphadenectomy were included in the study. The number of patients in the CDT and CDT-G groups was 8 and 11, respectively. There were no statistically significant differences between the CDT and CDT-G groups in terms of patient characteristics and severity of LLL before treatment. Reduction in ECW/TBW in the CDT-G group (in the whole body and the affected lower limb) after the intervention was significantly more remarkable than that in the CDT group., Conclusions: Goreisan-based Japanese herbal therapy may be effective in patients with LLL after retroperitoneal lymphadenectomy., Competing Interests: The authors declare that they have no competing interests., (Copyright © 2020 Nobuhisa Yoshikawa et al.)
- Published
- 2020
- Full Text
- View/download PDF
9. Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.
- Author
-
Yoshida K, Kajiyama H, Inami E, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Shibata K, Nawa A, and Kikkawa F
- Subjects
- Adult, Aged, Cell Line, Tumor, Cell Proliferation genetics, Female, Gene Expression Regulation, Neoplastic genetics, Gene Knockdown Techniques methods, Humans, Middle Aged, Prognosis, RNA, Small Interfering genetics, Uterine Cervical Neoplasms pathology, Young Adult, Carrier Proteins genetics, Uterine Cervical Neoplasms genetics
- Abstract
Background: Ubiquitin-associated protein 2-like (UBAP2L) has been demonstrated to be associated with the progression of multiple types of cancer. However, the function of UBAP2L in uterine cervical cancer remains unclear., Materials and Methods: Between 2005 and 2015, 84 patients who underwent surgery were included in this study. The patients were stratified into two groups on the basis of immunohistochemical staining for UBAP2L, and survival analysis was performed. Moreover, loss-of-function analysis was performed using the cervical cancer cell lines CaSki and SiHa., Results: Based on immunohistochemistry, the overall survival in patients with low UBAP2L expression was significantly longer than that of those with high UBAP2L expression (p=0.045). The in vitro experiment revealed that knockdown of UBAP2L remarkably inhibited cell proliferation in both live cell imaging and the MTS assay., Conclusion: Patients with high UBAP2L expression had unfavorable prognosis and UBAP2L appears to play an important role in proliferation., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
10. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background.
- Author
-
Yoshida K, Yokoi A, Kagawa T, Oda S, Hattori S, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Shibata K, Kajiyama H, Yokoi T, and Kikkawa F
- Subjects
- Animals, Carcinoma, Squamous Cell pathology, Female, Heterografts, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, MicroRNAs, Neoplasms, Multiple Primary pathology, Ovarian Neoplasms pathology, Sequence Analysis, RNA, Teratoma pathology, Carcinoma, Squamous Cell genetics, Cell Transformation, Neoplastic genetics, Neoplasms, Multiple Primary genetics, Ovarian Neoplasms genetics, Teratoma genetics
- Abstract
Owing to its rarity, the carcinogenesis and molecular biological characteristics of squamous cell carcinoma arising from mature teratoma remain unclear. This study aims to elucidate the molecular background of malignant transformation from the aspects of microRNA (miRNA) profiling. We examined 7 patients with squamous cell carcinoma and 20 patients with mature teratoma and extracted their total RNA from formalin-fixed paraffin-embedded tissues. Then we prepared small RNA libraries and performed comprehensive miRNA sequencing. Heatmap and principal component analysis revealed markedly different miRNA profiling in cancer, normal ovarian and mature teratoma tissues. Then we narrowed down cancer-related miRNAs, comparing paired-cancer and normal ovaries. Comparisons of cancer and mature teratoma identified two markedly upregulated miRNAs (miR-151a-3p and miR-378a-3p) and two markedly downregulated miRNAs (miR-26a-5p and miR-99a-5p). In addition, these findings were validated in fresh cancer tissues of patient-derived xenograft (PDX) models. Moreover, several miRNAs, including miR-151a-3p and miR-378a-3p, were elevated in the murine plasma when tumor tissues were enlarged although miR-26a-5p and miR-99a-5p were not elucidated in the murine plasma. Finally, we performed target prediction and functional annotation analysis in silico and indicated that targets genes of these miRNAs markedly correlated with cancer-related pathways, including 'pathway in cancer' and 'cell cycle'. In conclusion, this is the first study on miRNA sequencing for squamous cell carcinoma arising from mature teratoma. The study identified four cancer-related miRNAs that were considered to be related to the feature of malignant transformation. Moreover, miRNAs circulating in the murine plasma of the PDX model could be novel diagnostic biomarkers., (© The Author(s) 2019. Published by Oxford University Press.)
- Published
- 2019
- Full Text
- View/download PDF
11. Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma.
- Author
-
Kajiyama H, Suzuki S, Utsumi F, Yoshikawa N, Nishino K, Ikeda Y, Niimi K, Yamamoto E, Kawai M, Shibata K, Nagasaka T, and Kikkawa F
- Subjects
- Adenocarcinoma, Mucinous pathology, Adenocarcinoma, Mucinous secondary, Adenocarcinoma, Mucinous surgery, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Prognosis, Retrospective Studies, Survival Rate, Young Adult, Adenocarcinoma, Mucinous mortality, Neoplasm Recurrence, Local mortality, Ovarian Neoplasms mortality
- Abstract
Background: Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage., Materials and Methods: The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III-IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni- and multivariable analyses. Pathological slides were evaluated based on centralized pathological review., Results: The median age of patients with PmOC and MmOC was 55 (18-81) and 51 years (30-82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303-3.654), P = 0.0036]., Conclusion: The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.
- Published
- 2019
- Full Text
- View/download PDF
12. Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database.
- Author
-
Kajiyama H, Suzuki S, Utsumi F, Nishino K, Niimi K, Mizuno M, Yoshikawa N, Kawai M, Oguchi H, Mizuno K, Yamamuro O, Shibata K, Nagasaka T, and Kikkawa F
- Subjects
- Adult, Age Distribution, Aged, Aged, 80 and over, Databases, Factual, Female, Humans, Middle Aged, Neoplasm Metastasis, Ovarian Neoplasms complications, Stomach Neoplasms complications, Ovarian Neoplasms epidemiology, Stomach Neoplasms epidemiology
- Abstract
Malignant ovarian neoplasm is one of the most lethal malignancies among cancers of the female reproductive system. Occasionally, these tumors originate from non-ovarian organs as metastatic lesions since the ovary is a frequent metastatic target of many cancers. However, there limited clinical information on metastatic ovarian carcinoma (MOC) and its hallmarks are unknown. During the period of 1986-2015, 4,284 patients with malignant ovarian neoplasm were identified using the Tokai Ovarian Tumor Study Group (TOTSG) database. Of these, excluding borderline malignant tumor, 3,478 patients with malignant ovarian cancer were extracted. The pathological slides were evaluated under central pathological review. Among them, a total of 143 (4.1%) patients with MOC were identified. The median age of patients with MOC was 54 (29-82) years. The most and second most frequent original tumors were colorectal (43%, N=62) and gastric (29%, N=42) carcinoma, respectively. The rates of carcinoma of the appendix, breast, and pancreas were 8, 6, and 4%, respectively. This is the one of the largest studies clarifying the rates of MOC among malignant ovarian neoplasms. Although the rate is low, we should keep in mind that MOC, particularly from colorectal and gastric cancer should be considered when encountering clinical practice of ovarian cancer., Competing Interests: The authors declare that they have no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
13. Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?
- Author
-
Yoshida K, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, and Kikkawa F
- Subjects
- Adult, Aged, Female, Humans, Kaplan-Meier Estimate, Lymph Nodes pathology, Lymphatic Metastasis pathology, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local prevention & control, Pelvis pathology, Postoperative Care methods, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Uterine Cervical Neoplasms mortality, Lymph Nodes radiation effects, Lymphatic Metastasis radiotherapy, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery
- Abstract
Background: In cervical cancer, para-aortic lymph nodes are common sites of metastasis. The purpose of the study was to evaluate the clinical benefits of prophylactic irradiation as postoperative therapy., Methods: A retrospective cohort study was conducted during 2001-2015 at a single institution. Patients with a high risk of para-aortic lymph nodes recurrence were eligible for this study, and we identified patients who had pelvic lymph node metastasis and underwent radical surgery and concurrent chemo-radiotherapy. As a result, 33 and 46 patients were included in the treatment (prophylactic irradiation) and non-treatment groups, respectively. Baseline differences between the two groups were adjusted with the inverse probability of treatment weighting using propensity scores composed of the independent variables including age, stage, tumor size, pathological findings, lymph node status, and pathological subtypes., Results: In the 68-month median follow-up period (range 6-178 months), 25 patients experienced recurrence, and 17 patients were dead. After adjustment with the inverse probability of treatment weighting, the recurrence rates tended to decrease in the treatment group, but there was no significant difference between the two groups [treatment vs. non-treatment, 29.4% and 44.3%, respectively; hazard ratio, 0.593 (95% CI 0.320-1.099); P = 0.097]. However, adjusted para-aortic lymph nodes recurrence rates were not significantly different [treatment vs. non-treatment, 7.8% and 11.4%, respectively; odds ratio, 0.660 (95% CI 0.187-2.322); P = 0.558]. Moreover, Kaplan-Meier curves showing post-recurrence survival revealed no significant difference between the two groups (P = 0.141)., Conclusions: Prophylactic para-aortic lymph nodes irradiation did not reduce the risk of recurrence.
- Published
- 2019
- Full Text
- View/download PDF
14. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study.
- Author
-
Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, and Kikkawa F
- Subjects
- Adolescent, Adult, Cancer Survivors, Child, Child, Preschool, Female, Humans, Japan, Neoplasm Recurrence, Local mortality, Neoplasms, Germ Cell and Embryonal mortality, Ovarian Neoplasms mortality, Pregnancy, Pregnancy Outcome, Surveys and Questionnaires, Young Adult, Fertility Preservation, Neoplasm Recurrence, Local therapy, Neoplasms, Germ Cell and Embryonal therapy, Ovarian Neoplasms therapy
- Abstract
Background: Malignant ovarian germ cell tumors usually occur in young women. Until the 1970s, before establishment of systemic chemotherapy, malignant ovarian germ cell tumors had a very poor prognosis. Recently, prognosis has improved, and fertility-sparing treatment is being adopted in patients who desire to become pregnant. However, the number of malignant ovarian germ cell tumor survivors who actually became pregnant remains unknown., Objective: The present study aimed to clarify the reproductive outcomes in malignant ovarian germ cell tumor survivors by using data from a multicenter database and an additional survey on reproductive outcomes., Study Design: The study used the Tokai Ovarian Tumor Study Group database on ovarian cancer patients. We assessed the database from 1986 through 2016 and selected malignant ovarian germ cell tumor patients <40 years of age who received fertility-sparing treatment. Questionnaires on reproductive outcomes were sent to the registered facilities. The following data were collected and used in this study: age, date of onset, surgical procedure, chemotherapy regimen, tumor type, International Federation of Gynecology and Obstetrics stage, survival outcome and period, number of pregnancies and childbirths, marital status, childbearing desire, method of pregnancy, gestational weeks at delivery, birthweight of the baby, obstetric complications, and menstrual status after fertility-sparing treatment., Results: A total of 110 malignant ovarian germ cell tumor patients who received fertility-sparing treatment were identified. The median follow-up period was 10.4 years. Five patients were excluded because of death or loss of fertility after treatment for recurrence. Thus, 105 patients were finally included. The additional survey revealed that 42 of 45 patients who desired childbirth became pregnant. The total number of pregnancies was 65, and 56 babies were born to 40 malignant ovarian germ cell tumor survivors., Conclusion: The reproductive outcomes of malignant ovarian germ cell tumor survivor are promising with fertility-sparing treatment. Malignant ovarian germ cell tumor survivors can become pregnant and give birth if they desire., (Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
15. KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells.
- Author
-
Kawai Y, Shibata K, Sakata J, Suzuki S, Utsumi F, Niimi K, Sekiya R, Senga T, Kikkawa F, and Kajiyama H
- Subjects
- Adenocarcinoma, Clear Cell pathology, Aged, Apoptosis genetics, Cell Proliferation genetics, Disease-Free Survival, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms pathology, Adenocarcinoma, Clear Cell genetics, Biomarkers, Tumor genetics, Kinesins genetics, Ovarian Neoplasms genetics, Prognosis
- Abstract
Kinesin family member 20A (KIF20A), which is involved in cytokinesis and intracellular transportation, has been recently reported to be upregulated in several malignancies and may contribute to chemotherapeutic resistance. We examined the distribution and expression of KIF20A in clear‑cell carcinoma (CCC) of the ovary to elucidate its clinical significance and molecular mechanism. Paraffin sections from ovarian CCC tissues (N=43) were immunostained with KIF20A antibody, and the staining intensities were semi‑quantitatively evaluated. Furthermore, we investigated whether silencing of KIF20A contributes to the proliferation‑inhibitory potential using CCC cells. During the observational period, 18 patients (41.9%) developed recurrence. The median time to recurrence was 11.5 months. Patients in the high KIF20A expression group showed poorer progression‑free survival (PFS) and overall survival (OS) than those in the low expression group (P=0.0443 and P=0.0478, respectively). In multivariable analyses, KIF20A expression was also a significantly independent indicator of PFS and a marginally significant indicator of OS [PFS: HR (high vs. low), 5.488; 95% CI, 1.410‑24.772 (P=0.0136); OS: HR, 2.835; 95% CI, 0.854‑11.035, (P=0.0897)]. In in vitro studies, the ovarian CCC cell proliferation was significantly decreased by KIF20A silencing or in the presence of KIF20A inhibitor in CCC cells. Cell cycle G2/M arrest and a higher apoptosis‑induced fraction were more frequently observed in si‑KIF20A‑transfected CCC cells than in the control cells. Although the present study was preliminary, these data indicate the possible involvement of KIF20A in the proliferation of CCC, suggesting that targeting this molecule may contribute to reversing the malignant potential consequently affecting the oncologic outcome of CCC patients.
- Published
- 2018
- Full Text
- View/download PDF
16. The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.
- Author
-
Yoshida K, Suzuki S, Sakata J, Utsumi F, Niimi K, Yoshikawa N, Nishino K, Shibata K, Kikkawa F, and Kajiyama H
- Abstract
Vascular endothelial growth factor (VEGF) inhibitors have been utilized for the treatment against advanced or recurrent cervical carcinoma as a novel therapeutic modality. However, the expression level of VEGF in post-radiotherapy relapsed/persistent cervical cancer remains to be elucidated. The aim of the present study was to investigate the expression of VEGF and associated molecules using tumor samples from patients with post-radiotherapy relapsed/persistent cervical cancer. From a database of 826 patients who were treated at our institution between 2003 and 2015, eight patients with post-radiotherapy relapsed/persistent cervical cancer were identified, and 20 patients who underwent initial surgery alone were used as a control. Using samples from these patients, the expression levels of VEGF-A, VEGF receptor-1 (VEGFR-1) and hypoxia inducible factor-1α (HIF-1α) were immunohistochemically categorized as negative or weakly, moderately, or strongly positive according to the size of the staining area, and intensity. In carcinoma cells, the expression levels of VEGF-A, VEGFR-1 and HIF-1α were significantly higher in post-radiotherapy relapsed/persistent cervical cancer compared with control patients (P=0.0003, 0.0003, and 0.0001, respectively). In stroma cells, similar tendencies with statistical significance were observed (P=0.0014 and P<0.0001, respectively). In addition, the expression levels of VEGF-A and VEGFR-1 in carcinoma cells were significantly correlated with each other (P<0.0001). A significantly higher expression of VEGF was identified in post-radiotherapy relapsed/persistent cervical cancer compared with typical specimens from cervical cancer. The findings provide a novel insight into the clinical treatment for recurrent/persistent cervical cancer using a VEGF antagonist.
- Published
- 2018
- Full Text
- View/download PDF
17. Fertility-sparing surgery of malignant transformation arising from mature cystic teratoma of the ovary.
- Author
-
Yoshikawa N, Teshigawara T, Ikeda Y, Nishino K, Sakata J, Utsumi F, Niimi K, Sekiya R, Suzuki S, Kawai M, Shibata K, Kikkawa F, and Kajiyama H
- Abstract
Background: The purpose of this study was to evaluate the long-term clinical outcome of young women with malignant transformation arising from mature cystic teratoma of the ovary (MT-MCT) by comparing radical surgery and fertility-sparing surgery (FSS)., Patients and Methods: All patients treated with radical surgery or FSS for MT-MCT in multiple institutions were registered in this analysis. Univariate and multivariate analyses were performed to evaluate clinical outcome, including overall survival (OS) and disease-free survival (DFS)., Results: From 1986 to 2016, 62 patients with MT-MCT were treated in our group. The median follow-up period was 38.0 (2.0-227.9) months, and the median age was 54 (17-82) years old. Multivariate analysis revealed that only advanced stage was significantly correlated with poorer prognosis of patients [hazard ratio (HR) for death: 6.58, 95% confidence interval (CI): 1.82-24.78, P = 0.0048; HR for recurrence: 5.59, 95% CI: 1.52-21.83, P = 0.01]. Of a total of 13 women with stage I-II disease at less than 45 years old, 7 were treated with FSS, and there was no recurrence except for in one woman with stage II MT-MCT. There was no significant difference in long-term oncological outcome between radical surgery and FSS., Conclusion: FSS may be indicated for patients with stage I MT-MCT, who hope to preserve fertility, as no relapse was found after FSS., Competing Interests: CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
18. Novel potential photodynamic therapy strategy using 5-Aminolevulinic acid for ovarian clear-cell carcinoma.
- Author
-
Teshigawara T, Mizuno M, Ishii T, Kitajima Y, Utsumi F, Sakata J, Kajiyama H, Shibata K, Ishizuka M, and Kikkawa F
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2 antagonists & inhibitors, Cell Line, Tumor, Combined Modality Therapy, Female, Humans, Protoporphyrins biosynthesis, RNA, Messenger, Real-Time Polymerase Chain Reaction, Adenocarcinoma, Clear Cell drug therapy, Aminolevulinic Acid pharmacology, Ovarian Neoplasms drug therapy, Photochemotherapy methods, Photosensitizing Agents pharmacology
- Abstract
Background: Photodynamic therapy (PDT) is known as a minimally invasive treatment for cancer. 5-Aminolevulinic acid (ALA) is a precursor of the photosensitizing agent protoporphyrin IX (PpIX). Patients with ovarian clear-cell carcinoma (CCC) have poorer prognoses than those of patients with other histological CCC types. We evaluated the efficacy of ALA-PDT on CCC cells in vitro., Methods: We used seven human CCC cell lines to measure the cytotoxicity of ALA-PDT. PpIX production in cancer cells was measured using a micro-plate reader. Quantitative real-time PCR was performed to assess the mRNA levels of genes involved in the accumulation of PpIX in cancer cells. Additionally, we measured the enhancement in cytotoxicity with the use of an ABCG2 inhibitor., Results: We found that three cell lines were highly sensitive to ALA-PDT. In contrast, one cell line was resistant to ALA-PDT. The cytotoxicity of ALA-PDT varied among CCC cell lines. The IC50 values of ALA-PDT for the CCC cell lines had a wide range (30-882μM). The cytotoxicity of ALA-PDT was correlated with the intracellular PpIX accumulation. The cell lines sensitive to ALA-PDT expressed PEPT1 (an ALA uptake transporter). The cell line resistant to ALA-PDT expressed ABCG2 (a PpIX export transporter). In the resistant cell line, a combination treatment with both ALA and an ABCG2 inhibitor resulted in the promotion of cytotoxic sensitivity., Conclusion: The present study revealed the efficacy of ALA-PDT against CCC with chemoresistance in vitro., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
19. Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas.
- Author
-
Nakamura K, Kajiyama H, Utsumi F, Suzuki S, Niimi K, Sekiya R, Sakata J, Yamamoto E, Shibata K, and Kikkawa F
- Abstract
Uterine sarcomas are some of the most malignant and aggressive tumor types among the gynecologic malignancies, and they are associated with a high rate of recurrence and a poor prognosis. Due to their rarity and diversity, the optimal treatment for recurrent uterine sarcomas has not yet been elucidated. The aim of the present study was to investigate the potential of secondary cytoreductive surgery (SCS) for patients with recurrent uterine sarcomas. A total of 18 patients with recurrent uterine sarcomas were retrospectively identified at the Department of Obstetrics and Gynecology, Nagoya University (Nagoya, Japan) between January 2002 and December 2015. This included 8 patients with leiomyosarcoma, 6 with carcinosarcoma, 3 with endometrial stromal sarcoma and 1 with adenosarcoma. All patients underwent primary debulking surgery as the initial treatment. In summary, 9 patients were treated with SCS when they experienced their first recurrence, and the other 9 patients were treated with non-SCS methods, including chemotherapy or radiotherapy. In the SCS group, 5/9 patients had confined pelvic recurrences, 3 patients had extra-pelvic diseases, including pulmonary metastasis, and one patient had intra- and extra-pelvic recurrence. The 3-year overall survival (OS) rates were 77.8 and 11.1% in the SCS and non-SCS groups, respectively. The patients who underwent SCS experienced a significantly longer OS time compared with those in the non-SCS group (P=0.006). In addition, the disease-free survival after second-line therapy was significantly longer in the SCS group than in the non-SCS group (P=0.0496). These findings suggest that resection of recurrent uterine sarcomas may be beneficial for the improvement of patient survival. Prospective studies with sufficient statistical power are warranted for further evaluation of the effect of SCS.
- Published
- 2018
- Full Text
- View/download PDF
20. A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence.
- Author
-
Yoshida K, Kajiyama H, Utsumi F, Niimi K, Sakata J, Suzuki S, Shibata K, and Kikkawa F
- Abstract
The aim of the present study was to estimate the post-recurrence survival (PRS) of patients with relapsed uterine cervical cancer (RUCC). In addition, clinicopathological indicators that influenced PRS were investigated. Between 1998 and 2014, of 740 patients with cervical cancer, 165 patients experienced recurrence (recurrence rate, 22.3%), and 83 patients succumbed to the disease within a median follow-up of 34.3 months. A total of 151 stage Ib-IV patients who experienced recurrence after initial treatment for cervical cancer at our institute were analyzed. Uni- and multivariate analyses were performed using the Kaplan Meier method, and Cox regression model. The median age was 55 years (range, 20-88 years). In all, 80 patients succumbed to the disease. The median PRS time of all the patients was 28.4 months. The 1-, 3-, and 5-year PRS rates of patients were 75.1, 41.9, and 32.1%, respectively. In addition, the median survival period in patients who had received surgery as an initial treatment was significantly longer compared with that in patients who had not previously undergone surgery (36.7 vs. 23.3 months, respectively; P=0.0338). Following the univariate analysis, the median PRS in patients with in- and out-field recurrence was 12.6, and 45.9 months, respectively (P<0.0001). Furthermore, in the multivariable analysis, the recurrence site was a significant prognostic indicator of PRS [(In-field vs. Out-field); hazard ratio, 2.848; 95% confidence interval, 1.707-4.738; P<0.0001]. The long-term clinical outcome of patients with RUCC was poor. In particular, the in-field recurrence was identified to be associated with poor post-recurrence oncological outcome in patients with RUCC.
- Published
- 2018
- Full Text
- View/download PDF
21. The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours.
- Author
-
Kajiyama H, Suzuki S, Yoshihara M, Nishino K, Yoshikawa N, Utsumi F, Niimi K, Mizuno M, Kawai M, Oguchi H, Mizuno K, Yamamuro O, Nagasaka T, Shibata K, and Kikkawa F
- Abstract
The objective of this study was to estimate the frequency of possible occult metastasis through long-term survival analyses in patients with clear cell carcinoma (CCC) who had undergone complete resection. During the period of 1990-2015, 799 patients with stage I-IV CCC were identified in the TOTSG database. Of these, a total of 528 patients without a residual tumor were enrolled in the study and classified into four groups: Group 1: FIGO stage IA-IB (N=104), Group 2: FIGO stage IC1 (N=170), Group 3: FIGO stage IC2/IC3 (N=98), and Group 4: FIGO stage II-III (no residual tumor: N=156). Cumulative incidences of recurrence (CIR) and death (CID) were examined. The median age was 54, ranging from 29-87. The 5-year CIR / CID of each group were as follows: Group 1 (7.3% / 3.8%), Group 2 (14.3% / 10.2%), Group 3 (37.7% / 18.4%), and Group 4 (46.5% / 33.8%), respectively { P <0.0001 (recurrence) / P <0.0001 (death)}. Furthermore, confining analysis to relapsed patients, 1-, 2-, and 3-year CID after recurrence were 41.5, 60.9, and 73.9, respectively. Confining analyses to patients with sufficient information about adjuvant chemotherapy, the 5-year CIR / CID of stage IA-IC1 patients with or without chemotherapy were as follows: recurrence {13.0% (yes) / 9.6% (no)}, death {9.3% (yes) / 4.2% (no)}, respectively { P =0.947 (CIR) / P =0.224 (CID)}. CCC patients staged greater than IC2/ IC3 show a marked risk of mortality, even after complete surgical resection., Competing Interests: CONFLICTS OF INTEREST All authors declare that there are no conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
22. A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-β derived from ovarian cancer.
- Author
-
Fujikake K, Kajiyama H, Yoshihara M, Nishino K, Yoshikawa N, Utsumi F, Suzuki S, Niimi K, Sakata J, Mitsui H, Shibata K, Senga T, and Kikkawa F
- Subjects
- Carcinoma, Ovarian Epithelial, Cell Movement, Cell Proliferation, Coculture Techniques, Epithelial-Mesenchymal Transition, Epithelium metabolism, Epithelium pathology, Female, Humans, Neoplasms, Glandular and Epithelial pathology, Neovascularization, Pathologic metabolism, Ovarian Neoplasms pathology, Peritoneum cytology, Peritoneum metabolism, Peritoneum pathology, Tumor Cells, Cultured, Neoplasms, Glandular and Epithelial metabolism, Neovascularization, Pathologic pathology, Ovarian Neoplasms metabolism, Peritoneum blood supply, Transforming Growth Factor beta metabolism
- Abstract
Epithelial ovarian cancer (EOC) is believed to cause peritoneum dissemination through microenvironmental cell‑to-cell communication between the tumor and mesothelium, leading to the further acquisition of progressive and metastatic potentials. In the present study, we aimed to determine the role of cancer-associated mesothelial cells (CAMCs) in the promotion of tumor neovascularization and vascular permeability via enhanced vascular endothelial growth factor (VEGF) production. We examined whether a characteristic morphological change in human peritoneal mesothelial cells (HPMCs) was observed in the presence of malignant ascites and tumor-derived TGF-β. We focused on the enhanced production of VEGF in CAMCs and its crucial role in endothelial migration and tube formation. Normal HPMCs showed an epithelial morphology with a cobblestone appearance. When HPMCs were co-cultured with malignant ascites from patients with advanced EOC, a dramatic morphologic change was noted from an epithelioid pattern to an α-SMA-positive fibroblastic, mesenchymal pattern. Additionally, we found that EOC-derived TGF-β induced typical EMT-like morphological alteration in HPMCs, which was associated with CAMCs. We further discovered that CAMCs play a crucial role in the enhanced migration and tube formation of endothelial cells by the promotion of VEGF production. In conclusion, our findings indicate the possible involvement of CAMCs in the neovascularization of EOC and enhancement of vascular permeability, resulting in the formation of malignant ascites. The novel mechanism of CAMCs as a facilitator of EOC progression is displayed by microenvironmental cell-to-cell communication between EOC and the mesothelium.
- Published
- 2018
- Full Text
- View/download PDF
23. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
- Author
-
Tamauchi S, Kajiyama H, Utsumi F, Suzuki S, Niimi K, Sakata J, Mizuno M, Shibata K, and Kikkawa F
- Subjects
- Adult, Antineoplastic Agents, Hormonal administration & dosage, Female, Humans, Medroxyprogesterone Acetate administration & dosage, Recurrence, Antineoplastic Agents, Hormonal pharmacology, Endometrial Hyperplasia drug therapy, Endometrial Neoplasms drug therapy, Medroxyprogesterone Acetate pharmacology, Neoplasm Recurrence, Local drug therapy, Outcome Assessment, Health Care
- Abstract
Aim: Medroxyprogesterone acetate (MPA) is used to preserve fertility in patients with Grade 1 endometrial cancer without myometrial invasion (G1EA) and those with atypical endometrial hyperplasia (AEH). However, the efficacy of retreatment with MPA has not been sufficiently established for patients who experience recurrence but wish to retain their fertility. This study aimed to show the effectiveness of MPA treatment and retreatment for AEH and G1EA., Methods: A total of 39 patients received MPA treatment between 2005 and 2015, including nine with G1EA and 30 with AEH. The patients received high-dose (600 mg/day) MPA for 26 weeks. If a complete response was not achieved, MPA treatment was continued. After complete remission, if there was a recurrence, the patient was offered a choice of a hysterectomy or retreatment with MPA. The gynecologic and obstetric outcomes were retrospectively analyzed., Results: The median age was 34 years, and the median body mass index was 23.3 kg/m
2 . The median follow-up period was 52 months. Complete response rates for the initial treatment were 89% for G1EA and 93% for AEH. Recurrence occurred in 88% of patients with G1EA (7/8) and 50% of those with AEH (14/28). Seven patients with G1EA and 11 with AEH received MPA retreatment, and 100% and 92% of these achieved a complete response. During the study period, a total of 14 pregnancies were recorded with 10 live births., Conclusion: MPA can be effective for G1EA and AEH treatment even when they recur., (© 2017 Japan Society of Obstetrics and Gynecology.)- Published
- 2018
- Full Text
- View/download PDF
24. Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator.
- Author
-
Sakata J, Kajiyama H, Suzuki S, Utsumi F, Niimi K, Sekiya R, Shibata K, Senga T, and Kikkawa F
- Abstract
Several previous studies have revealed that the expression of zinc finger E-box binding homeobox 1 (ZEB1) in solid malignancies has an important significance on the clinical outcome of patients. However, the association between ZEB1 expression and survival in patients with epithelial ovarian carcinoma (EOC) remains unclear. The objective of the present study was to examine the extent of ZEB1 expression in EOC using immunohistochemical staining and investigate its association with patient outcome. A total of 40 patients with EOC initially treated with cytoreductive surgery and systematic chemotherapy were enrolled. ZEB1 expression was immunohistochemically categorized as negative, weak, moderate and strong according to the size of the staining area, and intensity. Subsequently, the associations between ZEB1 expression and recurrence/progression-free survival (RFS) rate were examined. The median age of patients in the current study was 54 years old (range, 22-72 years old). Among these patients, 15 (37.5%) exhibited International Federation of Gynecology and Obstetrics stage I disease, and 10 (25.0%), 13 (32.5%), and 2 (5%) had stage II, III, and IV disease, respectively. No patients with negative expression of ZEB1 experienced recurrence. In addition, ZEB1 expression was identified to be a significant predictor of a poorer RFS rate compared with negative expression (negative vs. weak, moderate and strong, P=0.0126). Furthermore, multivariate analyses revealed that moderate and strong ZEB1 expression levels were significant prognostic indicators of a poorer RFS rate in patients with EOC (hazard ratio, 2.265; 95% confidence interval, 1.072-8.021; P=0.0349). Confining analysis to patients with the clear-cell/mucinous histological type, those with moderate/strong ZEB1 expression demonstrated a significantly poorer RFS rate (P=0.0025). Positive ZEB1 expression may be an indicator to predict unfavorable RFS in patients with EOC.
- Published
- 2017
- Full Text
- View/download PDF
25. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells.
- Author
-
Sakata J, Utsumi F, Suzuki S, Niimi K, Yamamoto E, Shibata K, Senga T, Kikkawa F, and Kajiyama H
- Abstract
ZEB1, a member of the zinc-finger E-box binding homeobox family, is considered to play a crucial role in cancer progression and metastasis. In the current study, we investigated the role of ZEB1 in metastasis and chronic chemoresistance of epithelial ovarian carcinoma (EOC) cells. Using several EOC and acquired paclitaxel (PTX)-resistant EOC cell lines, we investigated whether silencing ZEB1 led to a reversal of the chemoresistance and metastatic potential in vitro and in vivo . Subsequently, the expression of ZEB1 in EOC tissues and its association with the oncologic outcome were investigated. According to the immunohistochemical staining of EOC tissues, as the positivity of ZEB1 expression was increased, the overall survival of EOC patients became poorer ( P = 0.0022 for trend). Additionally, cell migration and invasion were significantly decreased by ZEB1 silencing in both PTX-sensitive and PTX- resistant cells. Although PTX-sensitivity was not changed by silencing ZEB1 in parental EOC cells, the depletion of ZEB1 made the PTX-resistant EOC cells more sensitive to PTX treatment. In an animal model, mice injected with ZEB1-silencing PTX-resistant cells survived for longer than the control cell-injected mice. Although the intravenous injection of PTX did not affect the tumor weight of shCtrl cells, the tumor weight of shZEB1 cells was significantly reduced by PTX treatment. The current data indicate the possible involvement of ZEB1 in the metastasis and paclitaxel resistance of EOC, and suggest that targeting this molecule may reverse the malignant potential and improve the oncologic outcome for EOC patients., Competing Interests: CONFLICTS OF INTEREST All authors declare that there are no conflicts of interest.
- Published
- 2017
- Full Text
- View/download PDF
26. Novel Intraperitoneal Treatment With Non-Thermal Plasma-Activated Medium Inhibits Metastatic Potential of Ovarian Cancer Cells.
- Author
-
Nakamura K, Peng Y, Utsumi F, Tanaka H, Mizuno M, Toyokuni S, Hori M, Kikkawa F, and Kajiyama H
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cells, Cultured, Female, Gene Expression, Humans, Injections, Intraperitoneal, MAP Kinase Signaling System, Matrix Metalloproteinase 9 genetics, Matrix Metalloproteinase 9 metabolism, Mice, Models, Biological, Neoplasm Metastasis, Ovarian Neoplasms drug therapy, Ovarian Neoplasms mortality, Plasma Gases administration & dosage, Reactive Oxygen Species metabolism, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Plasma Gases pharmacology
- Abstract
Non-thermal atmospheric pressure plasma has been proposed as a new therapeutic tool for cancer treatment. Recently, plasma-activated medium (PAM) has been widely studied in various cancer types. However, there are only few reports demonstrating the anti-tumour effects of PAM in an animal model reflecting pathological conditions and the accompanying mechanism. Here we investigated the inhibitory effect of PAM on the metastasis of ovarian cancer ES2 cells in vitro and in vivo. We demonstrated that ES2 cell migration, invasion and adhesion were suppressed by PAM at a certain PAM dilution ratio, whereas cell viability remained unaffected. In an in vivo mouse model of intraperitoneal metastasis, PAM inhibited peritoneal dissemination of ES2 cells, resulting in prolonged survival. Moreover, we assessed the molecular mechanism and found that MMP-9 was decreased by PAM. On further investigation, we also found that PAM prevented the activation of the MAPK pathway by inhibiting the phosphorylation of JNK1/2 and p38 MAPK. These findings indicate that PAM inhibits the metastasis of ovarian cancer cells through reduction of MMP-9 secretion, which is critical for cancer cell motility. Our findings suggest that PAM intraperitoneal therapy may be a promising treatment option for ovarian cancer.
- Published
- 2017
- Full Text
- View/download PDF
27. Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer.
- Author
-
Utsumi F, Kajiyama H, Niimi K, Sekiya R, Sakata J, Suzuki S, Shibata K, Mizuno M, and Kikkawa F
- Subjects
- Adult, Aged, Female, Humans, Middle Aged, Prognosis, Time Factors, Ovarian Neoplasms drug therapy, Ovarian Neoplasms mortality, Terminal Care statistics & numerical data
- Abstract
Aim: Women with ovarian cancer (OC) often experience relapse and receive further repetitive chemotherapy. The objective of this study was to overview the remaining survival time after the final chemotherapy and to examine influential clinicopathologic indicators in those patients., Methods: The medical charts of deceased OC patients who had died of the disease between 2003 and 2012 were retrospectively reviewed. We investigated post-cancer-treatment survival (PCS) defined as the interval between the date of the final chemotherapy and death., Results: In all, 77 patients were enrolled. Three patients (3.9%) had received chemotherapy in the last 2 weeks. Eight (10.4%), 28 (36.4%), and 44 (57.2%) patients had received chemotherapy in the last 30, 60, and 90 days, respectively. There were no differences in either survival after recurrence or overall survival between the shorter (<75 days) and longer (≥75 days) PCS groups. On the other hand, patients in the shorter PCS group had significantly fewer chances of referral to a hospice or home-care than those in the latter group (P = 0.035). In multivariable analysis, a poorer performance status, an elevated white blood cell count, and a higher C-reactive protein value were significantly correlated with a shorter PCS (P = 0.004, 0.006 and 0.027, respectively)., Conclusion: Half of the patients received chemotherapy within 75 days of death and we did not identify any survival benefit in patients who received chemotherapy near the end of life. We should provide information to patients about their prognosis and discuss the timing of withdrawal from chemotherapy from the early stage of their recurrence., (© 2017 Japan Society of Obstetrics and Gynecology.)
- Published
- 2017
- Full Text
- View/download PDF
28. Future perspective of strategic non-thermal plasma therapy for cancer treatment.
- Author
-
Kajiyama H, Utsumi F, Nakamura K, Tanaka H, Toyokuni S, Hori M, and Kikkawa F
- Abstract
The therapeutic effects of non-thermal plasma are expected in the medical fields, including hemostasis, vascularization, prevention of organ adhesion, and cell proliferation. Cancer is an internal enemy arising from normal tissue in the body. The prognosis of metastatic and recurrent cancers is still poor despite advances in medicine. To apply non-thermal plasma in cancer treatment is now on going. The mechanism of the proliferation-inhibitory effect of plasma is reactive nitrogen oxide species/reactive oxygen species production in cells. There are a number of problems to be overcome, such as existence of intrinsic reactive oxygen species/reactive nitrogen species scavengers and the shallow infiltration of plasma on tumor surface. The current reviews makes referral to the study results of plasma therapy clarified so far, the possibility of its application in the future., Competing Interests: No potential conflicts of interest were disclosed.
- Published
- 2017
- Full Text
- View/download PDF
29. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer.
- Author
-
Nosaka K, Shibata K, Utsumi F, Yoshida K, Niimi K, Sekiya R, Suzuki S, Kajiyama H, and Kikkawa F
- Subjects
- Age Factors, Aged, Aged, 80 and over, Chemoradiotherapy adverse effects, Chemoradiotherapy methods, Comorbidity, Female, Humans, Kaplan-Meier Estimate, Neoplasm Staging, Patient Compliance, Retrospective Studies, Treatment Outcome, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms therapy
- Abstract
Background: Elderly patients with uterine cervical cancer reportedly have a poorer prognosis than younger patients. Until now, the benefit of concurrent chemoradiotherapy (CCRT) for elderly patients has been considered limited., Methods: We retrospectively analyzed 49 women with cervical cancer aged >70 years primarily treated with radiotherapy (RT) or CCRT in our institute between 2003 and 2014. Treatment compliance, toxicity, and survival benefit were analyzed., Results: A total of 49 patients were identified in this retrospective analysis. Twenty patients with a median age of 75.4 years (range 70-77) were treated with CCRT and 29 patients with a median age of 77.9 years (range 70-89) underwent RT. In the CCRT group, 14 patients (70%) completed CCRT consisting of radiotherapy and 5 courses of cisplatin plus 5-fluorouracil including patients requiring a dose reduction of chemotherapy. The median overall survival (OS) in the CCRT and RT groups was 66.9 and 60.1 months, respectively (p = 0.156). The most common grade 3/4 acute toxicity was hyponatremia (35.0%), followed by neutropenia (15.0%) and diarrhea (10.0%) in the CCRT group, while this was anemia (17.2%) followed by radiation enteritis (10.3%) in the RT group., Conclusions: CCRT was well tolerated in elderly patients with cervical cancer. Careful attention should be paid to the different characteristics of treatment-related toxicities in this group compared with younger patients.
- Published
- 2016
- Full Text
- View/download PDF
30. Oncologic and obstetric outcomes of early stage cervical cancer with abdominal radical trachelectomy: Single-institution experience.
- Author
-
Tamauchi S, Kajiyama H, Sakata J, Sekiya R, Suzuki S, Mizuno M, Utsumi F, Niimi K, Kotani T, Shibata K, and Kikkawa F
- Subjects
- Adult, Chemotherapy, Adjuvant, Female, Humans, Infertility, Female etiology, Neoplasm Staging, Pregnancy, Premature Birth etiology, Retrospective Studies, Trachelectomy methods, Treatment Outcome, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms pathology, Pregnancy Outcome, Trachelectomy adverse effects, Uterine Cervical Neoplasms surgery
- Abstract
Aim: Radical trachelectomy (RT) is a widely used fertility-sparing treatment for patients with early cervical cancer (CCA). RT, however, is an investigational treatment, and its gynecological and obstetric efficacy are being investigated. We retrospectively assessed the efficacy of abdominal RT (ART) as a fertility-sparing surgery., Methods: From 2010 to 2014, patients with stage IA2-IB1 CCA (tumor ≤2 cm) who wished to preserve their fertility underwent ART. The major outcomes were mortality, recurrence, pregnancy complications, and obstetric outcome., Results: Twenty-eight patients received ART. Adjuvant chemotherapy was performed in seven patients because of lymphovascular space invasion. During the median follow-up of 43 months, no recurrences occurred. Twelve women attempted to conceive, and eight of them became pregnant. A total of five children were born, and one baby was full term. Three cases of second trimester, and one case of third trimester preterm births were recorded., Conclusions: Fertility was preserved after ART in a moderate number of patients. The pregnancy and birth rates after ART have been improving, and increasing the full-term birth rate is the next goal. In addition, development of further types of minimally invasive surgery for CCA can be expected., (© 2016 Japan Society of Obstetrics and Gynecology.)
- Published
- 2016
- Full Text
- View/download PDF
31. Non-thermal atmospheric pressure plasma activates lactate in Ringer's solution for anti-tumor effects.
- Author
-
Tanaka H, Nakamura K, Mizuno M, Ishikawa K, Takeda K, Kajiyama H, Utsumi F, Kikkawa F, and Hori M
- Subjects
- Animals, Antineoplastic Agents pharmacology, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival, Humans, Lactic Acid pharmacology, Mice, Ringer's Solution, Xenograft Model Antitumor Assays, Antineoplastic Agents administration & dosage, Isotonic Solutions chemistry, Lactic Acid administration & dosage, Neoplasms drug therapy, Plasma Gases pharmacology
- Abstract
Non-thermal atmospheric pressure plasma is a novel approach for wound healing, blood coagulation, and cancer therapy. A recent discovery in the field of plasma medicine is that non-thermal atmospheric pressure plasma not only directly but also indirectly affects cells via plasma-treated liquids. This discovery has led to the use of non-thermal atmospheric pressure plasma as a novel chemotherapy. We refer to these plasma-treated liquids as plasma-activated liquids. We chose Ringer's solutions to produce plasma-activated liquids for clinical applications. In vitro and in vivo experiments demonstrated that plasma-activated Ringer's lactate solution has anti-tumor effects, but of the four components in Ringer's lactate solution, only lactate exhibited anti-tumor effects through activation by non-thermal plasma. Nuclear magnetic resonance analyses indicate that plasma irradiation generates acetyl and pyruvic acid-like groups in Ringer's lactate solution. Overall, these results suggest that plasma-activated Ringer's lactate solution is promising for chemotherapy.
- Published
- 2016
- Full Text
- View/download PDF
32. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.
- Author
-
Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, Kikkawa F, and Nakatsura T
- Abstract
Compared with other epithelial ovarian carcinoma subtypes, ovarian clear cell carcinoma (OCCC) has been recognized to show chemoresistance. Therefore, new treatment modalities are required for patients with OCCC that is refractory to chemotherapy. The carcinoembryonic antigen glypican-3 (GPC3) is expressed by approximately half of OCCC and is a promising immunotherapeutic target. The purpose of this study was to evaluate the effect of GPC3 peptide vaccine against refractory OCCC patients. We conducted a phase II trial with a GPC3-derived peptide vaccine in OCCC patients. Immunological responses were analyzed by ex vivo IFNγ ELISPOT assay. We also evaluated control subjects, who received best supportive care without vaccinations during the same period. Thirty-two patients with refractory OCCC were enrolled between July 2010 and September 2015, and underwent GPC3 peptide vaccination. Fifteen patients were vaccinated less than six times because their general condition progressively deteriorated, and 17 patients were vaccinated at least six times. Three patients showed a partial response as the best overall response. The GPC3 peptide vaccine induced a GPC3-specific CTL response in 15 out of 24 patients who had PBMCs collected three times or more. The prognosis of palliative care patients without GPC3 peptide vaccinations was significantly poorer than that of those with GPC3 peptide vaccinations (post cancer-treatment survival: p = 0.002). Although the disease control rate was not high, our results suggest that GPC3 peptide vaccinations may hold a significant impact to prolong survival of patients with refractory OCCC, allowing them to maintain quality of life with no serious toxicities.
- Published
- 2016
- Full Text
- View/download PDF
33. Variable susceptibility of ovarian cancer cells to non-thermal plasma-activated medium.
- Author
-
Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Mizuno M, Toyokuni S, Hori M, and Kikkawa F
- Subjects
- Cell Line, Tumor, Cell Proliferation, Cell Shape, Cell Survival drug effects, Culture Media, Drug Screening Assays, Antitumor, Female, Humans, Ovarian Neoplasms, Antineoplastic Agents pharmacology, Plasma Gases pharmacology
- Abstract
Non-thermal atmospheric pressure plasma has been widely studied in recent years in many fields, including cancer treatment. However, its efficiency for inducing apoptosis sometimes varies depending on the cell species and experimental conditions. The aim of this study was to elucidate what causes these differences in responses to plasma treatment. Using four ovarian cancer cell lines, the cell density had a markedly negative impact on the proliferation inhibition rate (PIR) and it was more obvious in OVCAR-3 and NOS2 cells. Furthermore, TOV21G and ES-2 cells were drastically sensitive to plasma‑activated medium (PAM) compared with the other two cell lines. We demonstrated that the proportion of reactive oxygen species and cell number had a marked impact on the effect of PAM against ovarian cancer cells. Additionally it was suggested that the morphological features of cells were also closely related to the sensitivity of cancer cells to the plasma treatment.
- Published
- 2016
- Full Text
- View/download PDF
34. Radiotherapy for persistent malignant transformation from mature cystic teratoma of the ovary.
- Author
-
Yoshida K, Kajiyama H, Utsumi F, Mitsui H, Shibata K, and Kikkawa F
- Abstract
Malignant transformations of mature cystic teratomas (MCT) are extremely rare and most of them are squamous cell carcinomas (SCC). Therefore no effective postoperative treatment has been established. In this article, we report two cases in which radiotherapy was effective for SCC arising from MCT. Case 1 was a 64-year-old woman with stage IIA of this tumor. After primary surgery, chemotherapy and interval debulking surgery were performed. She received radiotherapy for relapsed tumors, and has been well for 36 months since the initial diagnosis. Case 2 was a 37-year-old woman with stage IIB of this tumor. After primary debulking surgery, she received chemoradiotherapy for a residual tumor and has been well for 27 months since the surgery. Although there is no established therapy, radiotherapy or concurrent chemoradiotherapy might have beneficial effects on this tumor, similarly to those on SCC from other tissue., (© 2016 Japan Society of Obstetrics and Gynecology.)
- Published
- 2016
- Full Text
- View/download PDF
35. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
- Author
-
Yoshikawa N, Kajiyama H, Nakamura K, Utsumi F, Niimi K, Mitsui H, Sekiya R, Suzuki S, Shibata K, Callen D, and Kikkawa F
- Subjects
- Apoptosis drug effects, Carcinoma, Ovarian Epithelial, Cell Line, Tumor, Drug Resistance, Neoplasm, Drug Screening Assays, Antitumor, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Poly (ADP-Ribose) Polymerase-1 metabolism, Proteolysis, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Antineoplastic Agents pharmacology, Quinuclidines pharmacology, Reactive Oxygen Species metabolism
- Abstract
There is an intensive need for the development of novel drugs for the treatment of epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy due to the high recurrence rate. TP53 mutation is a common event in EOC, particularly in high-grade serous ovarian cancer, where it occurs in more than 90% of cases. Recently, PRIMA-1 and PRIMA‑1MET (p53 reactivation and induction of massive apoptosis and its methylated form) were shown to have an antitumor effect on several types of cancer. Despite that PRIMA-1MET is the first compound evaluated in clinical trials, the antitumor effects of PRIMA-1MET on EOC remain unclear. In this study, we investigated the therapeutic potential of PRIMA-1MET for the treatment of EOC cells. PRIMA-1MET treatment of EOC cell lines (n=13) resulted in rapid apoptosis at various concentrations (24 h IC50 2.6-20.1 µM). The apoptotic response was independent of the p53 status and chemo-sensitivity. PRIMA‑1MET treatment increased intracellular reactive oxygen species (ROS), and PRIMA-1MET-induced apoptosis was rescued by an ROS scavenger. Furthermore, RNA expression analysis revealed that the mechanism of action of PRIMA‑1MET may be due to inhibition of antioxidant enzymes, such as Prx3 and GPx-1. In conclusion, our results suggest that PRIMA-1MET represents a novel therapeutic strategy for the treatment of ovarian cancer irrespective of p53 status and chemo-sensitivity.
- Published
- 2016
- Full Text
- View/download PDF
36. The prognostic impact of pulmonary metastasectomy in recurrent gynecologic cancers: a retrospective single-institution study.
- Author
-
Adachi M, Mizuno M, Mitsui H, Kajiyama H, Suzuki S, Sekiya R, Utsumi F, Shibata K, Taniguchi T, Kawaguchi K, Yokoi K, and Kikkawa F
- Abstract
The aim was to examine the impact of pulmonary metastasectomy in patients with recurrent gynecologic cancers. Thirty-seven patients with isolated lung metastases (< 3 nodules) in recurrent epithelial gynecologic cancers were treated at Nagoya University Hospital between 1985 and 2013. The clinicopathological data for the 23 patients who underwent surgical resection were retrospectively analyzed, and their survival was compared with patients who received chemotherapy only. The median age at the time of surgery was 56 years (range 28-77). The studied population comprised 7 patients with 2 or 3 nodules and 8 patients with chemoresistant tumors, including fourteen cervical, 4 endometrial, and 5 ovarian primary tumors, with 5-year overall survivals (OSs) after surgery of 61, 100, and 100%, respectively. The survival of recurrence-free interval after initial treatment (>2 years) was significantly favorable (5-year OS 100% vs. 41.7%, p=0.006). Among the 6 patients with re-recurrence of lung metastases, 5 patients underwent a second pulmonary metastasectomy, and all of the patients are currently alive without disease. None of the 29 operations yielded severe complications. Although the survival rate showed a tendency to be higher in the surgery group than in the chemotherapy-only group, no significant difference was observed (5-year OS 81.7% vs. 49.5%, p=0.072). Our results indicate that pulmonary metastasectomy contributed to long-term survival with a low-risk of complications. Surgery to remove isolated lung metastases might provide a favorable prognosis for patients with long recurrence-free intervals and for patients with chemoresistant or re-recurrent tumors.
- Published
- 2015
37. Opioid needs of terminally ill patients with gynecologic malignancies.
- Author
-
Utsumi F, Kajiyama H, Sakata J, Higashi M, Niimi K, Sekiya R, Mitsui H, Suzuki S, Umezu T, Mizuno M, Yamamoto E, Shibata K, and Kikkawa F
- Subjects
- Age Factors, Female, Genital Neoplasms, Female pathology, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Ovarian Neoplasms complications, Ovarian Neoplasms pathology, Pain etiology, Pelvis, Retrospective Studies, Risk Factors, Uterine Cervical Neoplasms complications, Uterine Cervical Neoplasms pathology, Vaginal Neoplasms complications, Vaginal Neoplasms pathology, Vulvar Neoplasms complications, Vulvar Neoplasms pathology, Analgesics, Opioid administration & dosage, Genital Neoplasms, Female complications, Pain drug therapy, Terminal Care
- Abstract
Background: Little is known about patterns and predictive factors regarding opioid use for terminally ill patients with gynecologic malignancies. The aim of this study was to elucidate predictors affecting opioid requirements of end-of-life patients with gynecologic malignancies., Methods: A retrospective study was carried out on patients with gynecological malignancies admitted to our institute and died during the years 2002 to 2012. The association between maximum opioid dose and factors affecting opioid requirements were examined. Data extracted from medical records included age, site of primary cancer, maximum total dose of opioids prescribed over 24 h, the site of recurrence and metastasis, procedures performed during the hospital stay, total number of chemotherapy courses and overall survival., Results: The study identified 189 patients. Most patients had ovarian cancer (42.3 %) followed by cervical cancer (28.0 %) and then corpus malignancy (27.0 %). Opioid requirements decreased with increasing age, especially from the 50s onward. This was particularly marked in cervical cancer patients. In addition, pelvic metastasis was associated with the maximum dose of opioids and the average opioid use was highest in patients with cervical cancer., Conclusion: Young age and pelvic invasion were significant predictive factors regarding opioid requirements. Additionally, cervical cancer patients may require more opioids among those with gynecologic malignancies.
- Published
- 2015
- Full Text
- View/download PDF
38. Selective cytotoxicity of indirect nonequilibrium atmospheric pressure plasma against ovarian clear-cell carcinoma.
- Author
-
Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Hori M, and Kikkawa F
- Abstract
Ovarian clear cell carcinoma (CCC) is a histological type of epithelial ovarian cancer that is less responsive to chemotherapy and associated with a poorer prognosis than serous and endometrioid carcinoma. Non-thermal atmospheric pressure plasma which produces reactive species has recently led to an explosion of research in plasma medicine. Plasma treatment can be applied to cancer treatment to induce apoptosis and tumor growth arrest. Furthermore, recent studies have shown that a medium exposed to plasma also has an anti-proliferative effect against cancer in the absence of direct exposure to plasma. In this study, we confirmed whether this indirect plasma has an anti-tumor effect against CCC, and investigated whether this efficacy is selective for cancer cells. Non-thermal atmospheric pressure plasma induced apoptosis in CCC cells, while human peritoneal mesothelial cells remained viable. Non-thermal atmospheric pressure plasma exhibits selective cytotoxicity against CCC cells which are resistant to chemotherapy.
- Published
- 2014
- Full Text
- View/download PDF
39. Is there any association between where patients spend the end of life and survival after anticancer treatment for gynecologic malignancy?
- Author
-
Kajiyama H, Utsumi F, Higashi M, Sakata J, Sekiya R, Mizuno M, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Niimi K, Shibata K, and Kikkawa F
- Subjects
- Adult, Aged, Aged, 80 and over, Disease Progression, Female, Genital Neoplasms, Female drug therapy, Home Care Services, Hospice Care, Hospitalization, Humans, Japan, Middle Aged, Recurrence, Retrospective Studies, Survival Analysis, Time Factors, Young Adult, Antineoplastic Agents therapeutic use, Genital Neoplasms, Female mortality, Terminally Ill
- Abstract
Background: It remains unknown whether the end-of-life (EOL) environment influences survival after anticancer treatment, particularly for gynecologic malignancy., Objective: The study's objective was to clarify whether the survival time varied depending on where patients spend the EOL., Methods: This retrospective study included patients who received initial oncologic treatment but died due to cancer recurrence and/or progression. The subjects were a cohort of 181 gynecologic malignant tumor cases in a single institution from 2002 to 2008. Measurement was of postcancer treatment survival (PCS), defined as the time interval between the last date of anticancer treatment after recurrence/progression and death from the disease, analyzed on stratification by type of supportive care or where patients spent the EOL., Results: The median survival time was 26.1 (1.0-306.4) months. The distribution of the carcinoma type was as follows: 28.7% of patients with cervical (N=52), 27.6% with endometrial (N=50), and 43.1% with ovarian (N=79) cancer. The median PCS was 13.3 weeks. Patients in the hospice/home care group showed a significantly more favorable PCS than those in the hospital group (log rank: P=0.029). On multivariate analysis, the age (<60 versus ≥60) and site of supportive care (hospital versus hospice/home care) retained their significance as independent prognostic factors of poor PCS (age: HR=0.679, 95% CI, 0.496-0.928, P=0.0151; site of supportive care: HR=0.704, 95% CI, 0.511-0.970, P=0.0319)., Conclusions: Our current data could be hypothesis generating; it is possible that the EOL environment is a crucial prognostic factor for survival after anticancer treatment.
- Published
- 2014
- Full Text
- View/download PDF
40. Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo.
- Author
-
Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Mizuno M, Ishikawa K, Kondo H, Kano H, Hori M, and Kikkawa F
- Subjects
- Animals, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Apoptosis drug effects, Cell Line, Tumor, Cell Survival drug effects, Cisplatin therapeutic use, Drug Resistance, Neoplasm, Female, Humans, Mice, Mice, Nude, Paclitaxel, Taxoids therapeutic use, Xenograft Model Antitumor Assays, Atmospheric Pressure, Ovarian Neoplasms drug therapy, Plasma Gases therapeutic use
- Abstract
Purpose: Nonequilibrium atmospheric pressure plasma (NEAPP) therapy has recently been focused on as a novel medical practice. Using cells with acquired paclitaxel/cisplatin resistance, we elucidated effects of indirect NEAPP-activated medium (NEAPP-AM) exposure on cell viability and tumor growth in vitro and in vivo., Methods: Using chronic paclitaxel/cisplatin-resistant ovarian cancer cells, we applied indirect NEAPP-exposed medium to cells and xenografted tumors in a mouse model. Furthermore, we examined the role of reactive oxygen species (ROS) or their scavengers in the above-mentioned EOC cells., Results: We assessed the viability of NOS2 and NOS3 cells exposed to NEAPP-AM, which was prepared beforehand by irradiation with NEAPP for the indicated time. In NOS2 cells, viability decreased by approximately 30% after NEAPP-AM 120-sec treatment (P<0.01). The growth-inhibitory effects of NEAPP-AM were completely inhibited by N-acetyl cysteine treatment, while L-buthionine-[S, R]-sulfoximine, an inhibitor of the ROS scavenger used with NEAPP-AM, decreased cell viability by 85% after NEAPP-AM 60-sec treatment(P<0.05) and by 52% after 120 sec, compared to the control (P<0.01). In the murine subcutaneous tumor-formation model, NEAPP-AM injection resulted in an average inhibition of the NOS2 cell-inoculated tumor by 66% (P<0.05) and NOS2TR cell-inoculated tumor by 52% (P<0.05), as compared with the control., Conclusion: We demonstrated that plasma-activated medium also had an anti-tumor effect on chemo-resistant cells in vitro and in vivo. Indirect plasma therapy is a promising treatment option for EOC and may contribute to a better patient prognosis in the future.
- Published
- 2013
- Full Text
- View/download PDF
41. Granular cell tumor in the cerebellar meninx of an aged rat.
- Author
-
Aiuchi M, Utsumi F, Kobayashi K, Kurosaki E, and Sakuma S
- Subjects
- Aging, Animals, Cerebellar Neoplasms pathology, Cerebellum growth & development, Male, Meningeal Neoplasms pathology, Rats, Rats, Inbred Strains, Cerebellar Neoplasms veterinary, Meningeal Neoplasms veterinary
- Published
- 1986
- Full Text
- View/download PDF
42. Oligodendroglioma in an aged rat.
- Author
-
Aiuchi M, Utsumi F, Kobayashi K, Kurosaki E, and Sakuma S
- Subjects
- Animals, Brain Neoplasms pathology, Male, Microscopy, Electron, Oligodendroglioma pathology, Rats, Brain Neoplasms veterinary, Oligodendroglioma veterinary, Rats, Inbred Strains, Rodent Diseases pathology
- Published
- 1985
- Full Text
- View/download PDF
43. [A catheter for urinary catheterization].
- Author
-
Utsumi F and Takebayashi M
- Subjects
- Humans, Urinary Catheterization instrumentation
- Published
- 1987
44. Light and electron microscopic observations of ependyma in N-methyl-nitrosourea-induced dysgenetic hydromicrocephalic rat offsprings.
- Author
-
Aiuchi M, Kobayashi K, Utsumi F, and Sakuma S
- Subjects
- Aging, Animals, Ependyma growth & development, Ependyma ultrastructure, Female, Male, Methylnitrosourea, Microcephaly chemically induced, Pregnancy, Rats, Rats, Inbred Strains, Ependyma pathology, Microcephaly pathology
- Published
- 1986
- Full Text
- View/download PDF
45. A case of astrocytoma in an aged rat.
- Author
-
Aiuchi M, Utsumi F, Kobayashi K, Kurosaki E, and Sakuma S
- Subjects
- Animals, Astrocytoma ultrastructure, Brain Neoplasms ultrastructure, Cytoskeleton ultrastructure, Male, Rats, Astrocytoma veterinary, Brain Neoplasms veterinary, Rats, Inbred Strains, Rodent Diseases pathology
- Published
- 1984
- Full Text
- View/download PDF
46. Light and electron microscopic observations of choroid plexus in N-methyl-nitrosourea-induced dysgenetic hydromicrocephalic rat offsprings.
- Author
-
Aiuchi M, Kobayashi K, Utsumi F, and Sakuma S
- Subjects
- Age Factors, Animals, Female, Hydrocephalus chemically induced, Hydrocephalus pathology, Microcephaly chemically induced, Microcephaly pathology, Microscopy, Electron, Pregnancy, Rats, Rats, Inbred Strains, Rodent Diseases chemically induced, Choroid Plexus ultrastructure, Hydrocephalus veterinary, Methylnitrosourea, Microcephaly veterinary, Nitrosourea Compounds, Rodent Diseases pathology
- Published
- 1985
- Full Text
- View/download PDF
47. Light and electron microscopic observations of pia-arachnoid in N-methyl-nitrosourea-induced dysgenetic hydromicrocephalic rat offsprings.
- Author
-
Aiuchi M, Kobayashi K, Utsumi F, and Sakuma S
- Subjects
- Aging, Animals, Arachnoid ultrastructure, Brain growth & development, Female, Methylnitrosourea, Microcephaly chemically induced, Microscopy, Electron, Pia Mater ultrastructure, Pregnancy, Rats, Rats, Inbred Strains, Arachnoid pathology, Microcephaly pathology, Pia Mater pathology
- Published
- 1986
- Full Text
- View/download PDF
48. Pathology of non-effusive type feline infectious peritonitis and experimental transmission.
- Author
-
Hayashi T, Utsumi F, Takahashi R, and Fujiwara K
- Subjects
- Animals, Cats, Coronaviridae Infections pathology, Female, Male, Peritonitis pathology, Cat Diseases pathology, Coronaviridae Infections veterinary, Peritonitis veterinary
- Published
- 1980
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.